Eculizumab in STEC-HUS with severe neurological involvement: a New Zealand perspective.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Springer International Country of Publication: Germany NLM ID: 8708728 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-198X (Electronic) Linking ISSN: 0931041X NLM ISO Abbreviation: Pediatr Nephrol Subsets: MEDLINE
    • Publication Information:
      Publication: Berlin : Springer International
      Original Publication: Berlin : Springer International, c1987-
    • Subject Terms:
    • References:
      Wong W (2021) Shiga toxin producing Escherichia coli infections and associated haemolytic uraemic syndrome in New Zealand children: twenty three years of epidemiology and clinical observations. Int J Pediatr Res 8:085.
      Wildes DM, Harvey S, Costigan CS, Sweeney C, Twomey É, Awan A et al (2023) Eculizumab in STEC-HUS: a paradigm shift in the management of pediatric patients with neurological involvement. Pediatr Nephrol. https://doi.org/10.1007/s00467-023-06102-w.
      Pape L, Hartmann H, Bange FC, Suerbaum S, Bueltmann E, Ahlenstiel-Grunow T (20215) Eculizumab in typical hemolytic uremic syndrome (HUS) with neurological involvement. Medicine (Baltimore) 94:e1000.
      Giordano P, Netti GS, Santangelo L, Castellano G, Carbone V, Torres DD et al (2019) A pediatric neurologic assessment score may drive the eculizumab-based treatment of Escherichia coli-related hemolytic uremic syndrome with neurological involvement. Pediatr Nephrol 34:517–527. (PMID: 10.1007/s00467-018-4112-230362078)
    • Accession Number:
      A3ULP0F556 (eculizumab)
      0 (Antibodies, Monoclonal, Humanized)
    • Publication Date:
      Date Created: 20231130 Date Completed: 20240419 Latest Revision: 20240419
    • Publication Date:
      20240419
    • Accession Number:
      10.1007/s00467-023-06226-z
    • Accession Number:
      38032416